Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

▤ Summary

Cardiff Oncology announced positive Phase 2 results for onvansertib in first-line RAS-mutated metastatic colorectal cancer. The selected 30 mg dose combined with FOLFIRI/bevacizumab produced a higher confirmed response rate than standard of care and showed durable tumor shrinkage. The company said the treatment remained well tolerated with no new or overlapping toxicities. Cardiff Oncology also said it has completed its FDA End-of-Phase 2 meeting and plans to move into a registrational Phase 3 study. The company will host an investor webcast to discuss the data and next steps.

▦ Linked Companies